Free Trial
→ Massive July 4th Discount Inside (From Behind the Markets) (Ad) Free ACAD Stock Alerts

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

$15.59
-0.25 (-1.58%)
(As of 07/3/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 17 Analyst Ratings

Consensus Price Target

$28.71
84.13% Upside
High Forecast$42.00
Average Forecast$28.71
Low Forecast$19.00
TypeCurrent Forecast
7/5/23 to 7/4/24		1 Month Ago
6/5/23 to 6/4/24		3 Months Ago
4/6/23 to 4/5/24		1 Year Ago
7/5/22 to 7/5/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$28.71$28.94$36.12$26.29
Forecasted Upside84.13% Upside51.94% Upside52.75% Upside38.48% Upside

ACAD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ACADIA Pharmaceuticals Stock vs. The Competition

TypeACADIA PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.76
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside84.13% Upside1,007.94% Upside12.08% Upside
News Sentiment RatingPositive News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/27/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		E. Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOutperform$31.00+100.00%
6/25/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00+84.24%
5/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$26.00 ➝ $22.00+44.64%
5/9/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$33.00 ➝ $27.00+75.10%
5/9/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$30.19 ➝ $30.00+91.82%
5/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$37.00+130.53%
Massive July 4th Discount Inside (Ad)

To celebrate this Independence Day, we've arranged a special deal for you... We've partnered with Behind the Markets to make sure YOU get access to an exclusive 90% off sale not being offered to the public.

Claim your exclusive offer here>>>
5/9/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold ➝ Hold$26.00 ➝ $21.00+30.84%
5/9/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$31.00 ➝ $28.00+63.46%
5/9/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$30.00+75.13%
5/9/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$25.00 ➝ $21.00+22.59%
5/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $19.00+11.44%
3/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$29.00 ➝ $25.00+40.53%
3/13/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$40.00 ➝ $30.00+60.26%
2/7/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform ➝ Market Outperform$42.00+66.67%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy ➝ Buy$25.00+18.54%
10/17/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$33.00+38.77%
8/3/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$39.00 ➝ $38.00+36.01%
4/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$93.00 ➝ $95.00+363.41%
3/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$22.00 ➝ $25.00+28.80%
3/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$10.00 ➝ $15.00-22.72%
11/3/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Sell$15.00 ➝ $12.00-19.03%
11/1/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold$17.00+6.05%
8/9/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$27.00 ➝ $21.00+26.35%
8/8/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$32.00 ➝ $21.00+26.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:19 PM ET.

ACAD Forecast - Frequently Asked Questions

What is ACADIA Pharmaceuticals's stock forecast and purchase recommendation?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $28.71, with a high forecast of $42.00 and a low forecast of $19.00. The consensus rating for ACADIA Pharmaceuticals stock is Moderate Buy based on the current 4 hold ratings and 13 buy ratings for ACAD. Learn more on ACAD's analyst rating history.

Do Wall Street analysts like ACADIA Pharmaceuticals more than its competitors?

Analysts like ACADIA Pharmaceuticals more than other "medical" companies. The consensus rating score for ACADIA Pharmaceuticals is 2.76 while the average consensus rating score for "medical" companies is 2.71. Learn more on how ACAD compares to other companies.

Does ACADIA Pharmaceuticals's stock price have much upside?

According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 56.13% based on their 12-month stock forecasts.

What analysts cover ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has been rated by research analysts at Bank of America, BMO Capital Markets, Cantor Fitzgerald, Citigroup, HC Wainwright, Mizuho, Needham & Company LLC, Oppenheimer, Robert W. Baird, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.


Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ACAD) was last updated on 7/4/2024 by MarketBeat.com Staff

From Our Partners
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...
Priority Gold | Sponsored
270x more lucrative than NVIDIA???
If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...
Behind the Markets | Sponsored
Silver Expected for Extreme Price Action
Our newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...
Colonial Metals | Sponsored
Re: We’re giving you all this for less than a pair of socks
The Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...
StockEarnings | Sponsored
New Government Policy to Wipe Out Seniors Wealth
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...
Oasis Gold | Sponsored
Biden Nomination CANCELED?
And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...
The Freeport Society | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
DOLLAR RECALL ON THE AGENDA
Have you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...
Golden Crest | Sponsored